scispace - formally typeset
L

Leigh MacConell

Researcher at Amylin Pharmaceuticals

Publications -  32
Citations -  3048

Leigh MacConell is an academic researcher from Amylin Pharmaceuticals. The author has contributed to research in topics: Exenatide & Diabetes mellitus. The author has an hindex of 20, co-authored 29 publications receiving 2929 citations. Previous affiliations of Leigh MacConell include Bristol-Myers Squibb & AstraZeneca.

Papers
More filters
Journal ArticleDOI

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Richard M. Bergenstal, +8 more
- 07 Aug 2010 - 
TL;DR: The goal of many clinicians who manage diabetes is to achieve optimum glucose control alongside weight loss and a minimum number of hypoglycaemic episodes, and addition of exenatide once weekly to metformin achieved this goal more often than did addition of daily doses of either sitagliptin or pioglitazone.
Journal ArticleDOI

Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

Dennis Kim, +6 more
- 01 Jun 2007 - 
TL;DR: In this paper, the effects of continuous exenatide administration from a long-acting release (LAR) formulation were investigated in patients with type 2 diabetes, and the results showed that the drug reduced A1C, post-prandial and fasting glucose, and weight.
Journal ArticleDOI

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Thomas J. Moretto, +6 more
- 01 Aug 2008 - 
TL;DR: The aim of this study was to evaluate the efficacy and tolerability of exenatide monotherapy in patients with type 2 diabetes naive to antidiabetic agents and whose disease was inadequately controlled with diet and exercise alone.
Journal ArticleDOI

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.

Ralph A. DeFronzo, +5 more
- 10 Sep 2008 - 
TL;DR: Although this study was limited by a 2-week duration of exposure, data demonstrate that, exenatide had a greater effect than sitagliptin to lower postprandial glucose and a more potent effect to increase insulin secretion and reduce insulin secretion in T2D patients.
Journal ArticleDOI

Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes

Mary Beth DeYoung, +4 more
- 26 Oct 2011 - 
TL;DR: EQW is the first glucose-lowering agent that is administered once weekly, and in comparative trials, EQW improved hemoglobin A1c more than EBID, sitagliptin, pioglitazone, or insulin glargine and reduced fasting plasma glucose more thanEBID.